PubMed=16464451; DOI=10.1016/j.expneurol.2005.12.011
Pollock K., Stroemer P., Patel S., Stevanato L., Hope A.D., Miljan E.A., Dong Z.-P., Hodges H., Price J., Sinden J.D.
A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke.
Exp. Neurol. 199:143-155(2006)

PubMed=19343502; DOI=10.1007/s10529-009-9989-1
Thomas R.J., Hope A.D., Hourd P.C., Baradez M.-O., Miljan E.A., Sinden J.D., Williams D.J.
Automated, serum-free production of CTX0E03: a therapeutic clinical grade human neural stem cell line.
Biotechnol. Lett. 31:1167-1172(2009)

PubMed=19633272; DOI=10.1177/1545968309335978
Stroemer P., Patel S., Hope A.D., Oliveira C., Pollock K., Sinden J.D.
The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion.
Neurorehabil. Neural Repair 23:895-909(2009)

Patent=US7666672
Sinden J.D., Pollock K., Stroemer P.
Cell lines.
Patent number US7666672, 23-Feb-2010

PubMed=32374064; DOI=10.1002/stem.3191; PMCID=PMC7496241
Yoon Y., Kim H.S., Jeon I., Noh J.-E., Park H.J., Lee S., Park I.-H., Stevanato L., Hicks C., Corteling R., Barker R.A., Sinden J.D., Song J.
Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease.
Stem Cells 38:936-947(2020)